The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Seminar 11 – Survival of hospital pharmacy preparations – standards for quality and safety, where to go? An interactive debate
1. Current Status, Position
Senior scientist at the H:S Pharmacy and The Capital Regional Pharmacy in Copenhagen.
2. Education
- 1969: Cand. Pharm. from the Royal Danish School of Pharmacy
- 1974: Ph.d. in pharmacy. Theses: Radiation crosslinking of polyethylene
- 1976-1979 : Senior research fellow at RDSP
- 1979-1987: Assoc. professor at RDSP and research chemist at the Risoe National Laboratory
- 1986: Dr. pharm.Theses. Technical aspects of gas sterilisation of medical devices
- 1987-1996: Director of the Rigshospitalet Pharmacy
- Since1990: Assigned professor at University of Copenhagen, Faculty of Pharmaceutical Sciences
- 1995-1999: Chairman of the Assoc. of Danish hospital pharmacy directors
- 1996 – 2005: Director of the H:S Pharmacy
- Since 2005: Director of Education, Science and Research. European Association of Hospital Pharmacists (EAHP), Bruxelles.
- Since 2005: Senior Scientist at the H:S Pharmacy and The Capital Regional Pharmacy
- Since 2008: Chairman of work group 16, European Pharmacopeia Commission. Strasbourg (Plastic materials and Containers).
- Since 2008: Member of the Working Party on the Quality of Pharmacy Preparations under the Committee of experts on quality and safety standards in pharmaceutical care. European Directorate for the Quality of Medicines and Health Care (EDQM), Strasbourg.
3. Research area
Prof. Dr. Vagn Handlos focuses his research on:
- Cytotoxic drugs in the workplace of Scandinavian hospital pharmacies.Robotics for hospital pharmacy preparation (www.SafeChemo.eu);
- Plastic materials as packing materials for drugs;
- Development within targeted therapy for Glioblastoma Multiforme using molecules coupled with toxins.